Hormone Resistant Prostate Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation; Prostate Carcinoma Metastatic in the Bone; Prostate Small Cell Carcinoma; Stage IV Prostate Adenocarcinoma Interventions: Drug: Cediranib; Other: Laboratory Biomarker Analysis; Drug: Olaparib Sponsor: National Cancer Institute (NCI) Not yet recruiting - verified September 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2016 Category: Research Source Type: clinical trials

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer Interventions: Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment; Drug: Trametinib Sponsors: Jonsson Comprehensive Cancer Center; National Cancer Institute (NCI) Not yet recruiting - verified August 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2016 Category: Research Source Type: clinical trials